PPD teams up with Cancer Treatment Centers of America to boost oncology trials

PPD
Using PPD's so-called Optimal Just-in-Time service, it paired up with Cancer Treatment Centers of America on its network of hospitals. (PPD)

PPD is working with Cancer Treatment Centers of America (CTCA) to speed up enrollment into cancer studies.

Using the CRO’s so-called Optimal Just-in-Time service (part of PPD’s Accelerated Enrollment Solutions business unit), it paired up with CTCA on its network of hospitals.

Working together, the two groups have “significantly shortened site activation time from as long as eight months to as little as two weeks … Metrics generated by CTCA demonstrate results that surpass traditional sites on the same trials when evaluating data currency, query rates, deviations and retention,” PPD said in a statement.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

PPD’s approach here is based on establishing a community of sites with prenegotiated contracts and terms, which provides “immediate engagement by sites to search for patients.” It explains that patients are identified first, triggering the activation of sites and enabling patients to be enrolled within two weeks. As a result of the efficiencies of this process, there are zero non-enrolling sites.

“Our collaboration with CTCA demonstrates how we are changing the paradigm of cancer care,” says Krystyna Kowalczyk, chief operating officer for Optimal service offerings.

“Together, we are creating meaningful opportunities for cancer patients to participate in clinical trials and access innovative therapies close to home, allowing them to receive care within the context of their support networks in their own communities. Some 30% of the patients we enroll with CTCA are from under-represented populations, which reflects our goal of expanding clinical trial opportunities more broadly. Our goal is to enroll more patients from fewer sites in less time to support important oncology trials. Thanks to our JIT methodology, a two-week turnaround for first-patient-in is now possible.”

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.